



October 29, 2026

To,
Listing/ Compliance Department
BSE LTD.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

SCRIP CODE: 543748

Dear Sir/Madam,

To,
Listing/ Compliance Department
National Stock Exchange of India Limited
"Exchange Plaza", Plot No. C/1,
G Block, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

SYMBOL: AARTIPHARM

Sub: Results Presentation
Ref: Regulation 30 of the SEBI (LODR)
Regulations 2015

Please find enclosed herewith the Q2 FY27 Results Presentation of the Company for your records.

The same is also being uploaded on the Company's website:

<https://www.aartipharmalabs.com/presentation>

Please take the same on your records.

Thanking you,

Yours faithfully,

For AARTI PHARMALABS LIMITED

Jeevan
Bhargav
Mondkar

Digitally signed by
Jeevan Bhargav
Mondkar
Date: 2026.10.29
13:24:42 +05'30'

JEEVAN MONDKAR

COMPANY SECRETARY AND LEGAL HEAD

ICSI M. NO. A22565

Encl. a/a.

AARTI PHARMALABS LIMITED

www.aartipharmalabs.com | CIN : L24100GJ2019PLC110964 | Email : info@artipharmalabs.com

Admin Office : 204, Udyog Kshetra, 2nd Floor, Mulund - Goregaon Link Road, Mulund (W), Mumbai, PIN - 400 080, Maharashtra, INDIA, T : +91 22 67976666 | F : +91 22 25653234
Regd. Office : Plot No. 22-C/1 & 22-C/2, 1st Phase, G.I.D.C., Vapi 396 195, District - Valsad, Gujarat, INDIA, T : +91 260 2400467, +91 99099 94655



INVESTOR PRESENTATION

October 2026

25 Years of Pharmaceutical Excellence



220+ Products
65 Patents Filed



500+ Global Clients
50+ Export Countries



3 State-of-the-art
R&D facilities



7 Manufacturing
Units
3 USFDA Units



2,500+ Employees



60 US DMF
44 CEP



15-20% Global
Market Share
in Xanthine



0.37x Net Debt/Equity



AA- Credit rating



1
**COMPANY
OVERVIEW**

2
**BUSINESS
OVERVIEW**

3
**STRATEGIC
OVERVIEW**

4
**FINANCIAL
OVERVIEW**



COMPANY OVERVIEW



- Aarti Pharmalabs Limited (APL) is part of the Aarti group – a diversified chemical conglomerate with group turnover of INR 145+ bn (FY26)
- Globally recognized manufacturer of generic API, Xanthine derivatives (Worlds third largest capacity) and a leading player in CDMO/CMO services
- Demonstrated strong expertise in development of robust & cost-effective process for rapid scale up and commercial production
- Received accreditation from several agencies, including USFDA, EU GMP, EDQM (European Pharmacopoeia), KFDA (Korea), and COFEPRIS (Mexico)
- Strategically located in western India with proximity to ports

HIGHLIGHTS



One of the leading small molecule CDMO/CMO company in India.




Regulatory focussed operations with expertise in novel chemistries;




Largest manufacturer of Xanthine Derivatives in India


STANDALONE REVENUE (INR Mn)
& EBITDA MARGINS (%)




GEOGRAPHICAL SALES (H1-FY27)



KEY MILESTONES



GEOGRAPHICAL PRESENCE




LOCATION	MANUFACTURING UNITS	CERTIFICATIONS & AUDIT DATE
Dombivli	Unit - I (API, Intermediates, CDMO)	USFDA - Jun 2022
Vapi	Unit - II (API, Intermediates, CDMO) Custom Synthesis Division	USFDA - Sep 2009, Aug 2017
Tarapur	Unit - III (Xanthine Unit)	USFDA - Mar 2008, Sep 2011, Mar 2015, Dec 2016, Feb 2020 EUGMP - Apr 2008, May 2012, Aug 2013, Jan 2015 EDQM - Sep 2019, KFDA - Nov 2017, COFEPRIS - Apr 2017, May 2017
	Unit - IV (API, CDMO-API)	
	Unit - V (Xanthine Unit)	
	Unit - VI (Intermediate unit of Xanthine, speciality & allied products)	
Atali	Atali Unit (Intermediates, CDMO)	

 HEAD OFFICE

 R&D CENTER

 MANUFACTURING UNIT

END TO END CAPABILITIES UNDER ONE UMBRELLA



TECHNICAL CAPABILITIES

MANUFACTURING CAPABILITIES

RESEARCH & DEVELOPMENT



3

State of the art
R&D Centers at
Maharashtra & Gujarat

40+

Products developed and
manufactured on kilo-lab
scale in FY26

19

New products
launched at plant
scale in FY26

8.5%

R&D Spend (as a percent
of API/Int & CDMO sales)
in H1FY27

18

PhDs

120

R&D Process Scientists

39 Cr

R&D Spend in H1FY27

61

APIs commercialized

65

Process Patents Filed

33

Patents Granted



1
COMPANY
OVERVIEW

2
BUSINESS
OVERVIEW

3
STRATEGIC
OVERVIEW

4
FINANCIAL
OVERVIEW



XANTHINE DERIVATIVES & ALLIED PRODUCTS



- World's third-largest and India's largest manufacturer of Xanthine Derivatives, including Caffeine (largest capacity in India), Theophylline Anhydrous, Aminophylline, Etophylline, and Theophylline.
- Non-Chinese dependent and fully backward integrated manufacturer of Xanthine derivatives, offering strong geographical diversification amidst “China+1” shift.
- Two dedicated plants at Tarapur, Maharashtra with a combined capacity of 9,600+ MTPA for producing Xanthine Derivatives.
- Capacity expanded from 5000 MTPA to 9,600+ MTPA, with phased ramp-up underway till FY27 end.
- Expanded capacity is expected to drive global market share from 15–20% to 20–25%.

END USE



Cola Drinks



Energy Drinks



Pharmaceutical




Nutraceutical


CERTIFICATIONS



SALES QUANTITY SPLIT (H1-FY27)



GEOGRAPHICAL SALES SPLIT (H1-FY27)



API & INTERMEDIATES



- Specialized player in the development and manufacturing of HPAPIs, catering to the demand for critical drugs used in oncology, corticosteroids, and cytotoxic medicines.
- Backward integrated for most APIs, with control over entire production value chain and ensuring high-quality intermediates.
- With USFDA approved manufacturing facilities and dedicated US, EU and Japan approvals, APL enjoys a distinct advantage over competition
- Preferred partner in regulated markets driven by robust regulatory documentation and IPR support
- 1,500+ KL multipurpose reactor capacity (fungible) and 14 API finished lines

KEY HIGHLIGHTS

61 APIs Commercialized

9 New APIs under development (R&D / validation)

60 US DMF Approvals


44 CEP Approvals

140+ Intermediates


THERAPEUTIC SEGMENT



MARKET SEGMENTATION (H1-FY27)



GEOGRAPHICAL SALES SPLIT (H1-FY27)



CDMO & CMO



- Amongst leading small molecule CDMO/CMO players in India, working with big pharma, innovators and biotech companies.
- Offering end to end services including process development and manufacturing of KSMs, RSMs, Intermediates & GMP APIs for small molecule NCEs, from early clinical phase (Phase 1,2,3), launch to commercial supplies
- Experienced in complex chemistries like cyanation, flow chemistry, nucleotides amongst others.
- Supported by 3 R&D centers and pilot facilities focusing on CDMO. Presently working with 23 customers on 59 active projects, of which 39 are in the commercial stage and 20 are under different stages of development, both at customer's end.
- Expanding on-ground sales presence to USA and EU, to strategically enhance CDMO global footprint.

SERVICES OFFERED



End-to-end solutions from synthetic route design to commercial manufacturing, specializing in HPAPIs, cryogenic reaction & corticosteroids development




Comprehensive services like
1) Robust process development (DoE & QbD studies)
2) Process validation and
3) Analytical method development & validation




Strong CMC documentation expertise to ensure smooth regulatory approvals.

CDMO Sales (INR Cr)




CDMO Customers & Projects



*Note: In chart, FY27E indicates estimated sales for FY27

SEGMENTAL SHARE & QUARTERLY HIGHLIGHTS

REVENUE BREAKUP Q2-FY27



OPERATIONAL HIGHLIGHTS Q2-FY27


- RM costs stay elevated due to geopolitical tensions. The increase is being passed on, for majority of the products.
- Capacity expansion done in Q1FY27 in Steroid Block at API Plant (Tarapur-4) has started contributing towards production as well as sales.
- In API segment, headwinds are subsiding; continuous cost optimization on current products helping position us for medium-term profitability.
- Both phases of Atali Block 1 have been operationalized.

1
COMPANY
OVERVIEW

2
BUSINESS
OVERVIEW

3
STRATEGIC
OVERVIEW

4
FINANCIAL
OVERVIEW



Brownfield Capex – Atali Block 2

	Site	Unit 7, Atali, Gujarat
	Estimated Investment	INR 149 crores
	Estimated Capacity	~405 KL
	Timeline	Commercialization by H2FY28
	Product Focus	CDMO/CMO
	Strategic Rationale	• Dedicated for certain CDMO / CMO projects, thereby ensuring supply continuity to large pharma customers • Cost effective design to yield better payback

FUTURE OUTLOOK

Targeting
15-18%

Revenue & EBITDA CAGR
Over the Next 3-4 Years



FY26 CAPEX reached
~ INR 400 cr; FY27
outlook expected at
similar levels



Initiating R&D investment in
FY27 towards TIDES (Peptides
& Oligonucleotides) to
expand portfolio capabilities.



Capex for Atali Block 2 with 400+ kL
dedicated capacity is ongoing.
Groundbreaking has been done.

1
COMPANY
OVERVIEW

2
BUSINESS
OVERVIEW

3
STRATEGIC
OVERVIEW

4
FINANCIAL
OVERVIEW



QUARTERLY STANDALONE INCOME STATEMENT

PARTICULARS (INR Mn)	Q2-FY27	Q1-FY27	Q-o-Q	Q2-FY26 #	Y-O-Y
Operational Revenue	6,126	5,346	14.6%	4,173	46.8%
Operating Expenses	4,768	4,019	18.6%	3,432	38.9%
EBITDA	1,358	1,327	2.3%	741	83.3%
EBITDA Margin (%)	22.17%	24.82%	(265) Bps	17.76%	441 Bps
Depreciation and Amortisation	305	300	1.7%	248	23.0%
Finance costs	150	129	16.3%	107	40.2%
Foreign Exchange (Gain)/Loss	(5)	(35)	(85.7)%	104	(104.8)%
Other Income	5	29	(82.8)%	36	(86.1)%
PBT before Exceptional Items	913	962	(5.1)%	318	187.1%
Exceptional Items	(20)	-	NA	-	NA
PBT	893	962	(7.2)%	318	180.8%
Tax Expense	235	249	(5.6)%	83	183.1%
PAT	658	713	(7.7)%	235	180.0%
PAT Margin (%)	10.74%	13.34%	(260) Bps	5.63%	511 Bps
Other Comprehensive Income	(15)	18	NA	(26)	(42.3)%
Total Comprehensive Income	643	731	(12.0)%	209	207.7%
Diluted EPS (INR)	7.24	7.86	(7.9)%	2.59	179.5%

Recognition of fair value movement on a long-dated USD forward contract under FVTPL impacted reported profitability during the period, with previous quarterly figures restated accordingly.

HALF YEARLY STANDALONE INCOME STATEMENT

PARTICULARS (INR Mn)	H1-FY27	H1-FY26 #	Y-O-Y
Operational Revenue	11,472	7,926	44.7%
Operating Expenses	8,787	6,234	41.0%
EBITDA	2,685	1,692	58.7%
EBITDA Margin (%)	23.40%	21.35%	205 Bps
Depreciation and Amortisation	606	475	27.6%
Finance costs	278	175	58.9%
Foreign Exchange (Gain)/Loss	(40)	142	(128.2)%
Other Income	34	43	(20.9)%
PBT before Exceptional Items	1,875	943	98.8%
Exceptional Items	(20)	-	NA
PBT	1,855	943	96.7%
Tax Expense	484	231	109.5%
PAT	1,371	712	92.6%
PAT Margin (%)	11.95%	8.98%	297 Bps
Other Comprehensive Income	3	(15)	(120.0)%
Total Comprehensive Income	1,374	697	97.1%
Diluted EPS (INR)	15.10	7.86	92.1%

Recognition of fair value movement on a long-dated USD forward contract under FVTPL impacted reported profitability during the period, with previous quarterly figures restated accordingly.

HISTORICAL STANDALONE INCOME STATEMENT

PARTICULARS (INR Mn)	H1-FY27	FY26	FY25	FY24
Operational Revenue	11,472	17,976	17,714	15,021
Operating Expenses	8,787	13,915	13,449	11,560
EBITDA	2,685	4,061	4,265	3,461
EBITDA Margin (%)	23.40%	22.59%	24.08%	23.04%
Depreciation and Amortisation	606	1,043	791	660
Finance costs	278	469	256	166
Foreign Exchange (Gain)/Loss	(40)	332	(17)	-
Other Income	34	153	128	110
PBT before Exceptional Items	1,875	2,370	3,363	2,745
Exceptional Items	(20)	28	-	-
PBT	1,855	2,342	3,363	2,745
Tax Expense	484	580	790	738
PAT	1,371	1,762	2,573	2,007
PAT Margin (%)	11.95%	9.80%	14.53%	13.36%
Other Comprehensive Income	3	(39)	(51)	1
Total Comprehensive Income	1,374	1,723	2,522	2,008
Diluted EPS (INR)	15.10	19.42	28.38	22.14

HISTORICAL STANDALONE BALANCE SHEET

ASSETS (INR Mn)	FY25	FY26	H1-FY27
Assets			
Non-current assets			
Property, plant and equipment	10,135	13,359	14,092
Capital work-in-progress	3,009	3,052	3,082
Right-to-use assets	153	655	567
Other Intangible assets	306	360	346
Intangible assets under development	678	879	1,039
Financial assets			
Investment in Subsidiary & Joint Control	135	135	135
Investments (others)	276	305	298
Loan	73	78	80
Other Financial Assets	135	352	360
Other non-current assets	208	168	87
Total of Non-current assets	15,108	19,343	20,086
Current assets			
Inventories	5,442	6,362	7,882
Financial assets			
Investments	159	-	-
Trade receivables	5,526	5,866	6,951
Cash and cash equivalents	28	55	12
Bank balances other than above	7	11	191
Loans	8	5	6
Other financial assets	11	-	2
Other current assets	875	1,536	1,533
Current Tax Assets (Net)	32	99	-
Total of Current assets	12,088	13,934	16,577
Total Assets	27,196	33,277	36,663

EQUITY & LIABILITIES (INR Mn)	FY25	FY26	H1-FY27
Equity & Liabilities			
Equity share capital	453	453	453
Other equity	17,986	19,370	20,579
Total equity attributable to equity holders	18,439	19,823	21,032
Liabilities			
Non-current liabilities			
Financial liabilities			
Borrowings	1,036	1,858	1,598
Lease liabilities	117	522	435
Other Financial Liabilities	150	394	369
Provisions	71	78	91
Deferred Tax Liabilities (Net)	1,196	1,343	1,426
Total of Non-current liabilities	2,570	4,195	3,919
Current liabilities			
Financial liabilities			
Borrowings	2,913	4,998	6,766
Lease liabilities	50	166	172
Trade Payables	2,490	3,243	3,567
Other financial liabilities	466	637	769
Provisions	105	112	190
Current Tax Liabilities (Net)	-	-	33
Other Current Liabilities	163	103	215
Total of Current liabilities	6,187	9,259	11,712
Total Liabilities	8,757	13,454	15,631
Total Equity & Liabilities	27,196	33,277	36,663

QUARTERLY CONSOLIDATED INCOME STATEMENT

PARTICULARS (INR Mn)	Q2-FY27	Q1-FY27	Q-o-Q	Q2-FY26 #	Y-O-Y
Operational Revenue	6,105	5,358	13.9%	4,183	45.9%
Operating Expenses	4,759	4,032	18.0%	3,436	38.5%
EBITDA	1,346	1,326	1.5%	747	80.2%
EBITDA Margin (%)	22.05%	24.75%	(270) Bps	17.86%	419 Bps
Depreciation and Amortisation	305	300	1.7%	248	23.0%
Finance costs	150	129	16.3%	107	40.2%
Foreign Exchange (Gain)/Loss	(5)	(35)	(85.7)%	104	(104.8)%
Other Income	5	5	NA	6	(16.7)%
PBT before Joint Venture & Exceptional Items	901	937	(3.8)%	294	206.5%
Exceptional Items (Net of Tax Expenses)	(20)	-	NA	-	NA
PBT before Joint Venture	881	937	(6.0)%	294	199.7%
Share of JV	69	74	(6.8)%	(6)	NA
PBT	950	1,011	(6.0)%	288	229.9%
Tax Expense	235	250	(6.0)%	83	183.1%
PAT	715	761	(6.0)%	205	248.8%
PAT Margin (%)	11.71%	14.20%	(249) Bps	4.90%	681 Bps
Other Comprehensive Income	(26)	17	NA	(8)	225.0%
Total Comprehensive Income	689	778	(11.4)%	197	249.7%
Diluted EPS (INR)	7.87	8.39	(6.2)%	2.26	248.2%

Recognition of fair value movement on a long-dated USD forward contract under FVTPL impacted reported profitability during the period, with previous quarterly figures restated accordingly.

HALF YEARLY CONSOLIDATED INCOME STATEMENT

PARTICULARS (INR Mn)	H1-FY27	H1-FY26 #	Y-O-Y
Operational Revenue	11,462	8,045	42.5%
Operating Expenses	8,789	6,344	38.5%
EBITDA	2,673	1,701	57.1%
EBITDA Margin (%)	23.32%	21.14%	218 Bps
Depreciation and Amortisation	606	476	27.3%
Finance costs	278	175	58.9%
Foreign Exchange (Gain)/Loss	(40)	142	(128.2)%
Other Income	9	12	(25.0)%
PBT before Joint Venture & Exceptional Items	1,838	920	99.8%
Exceptional Items (Net of Tax Expenses)	(20)	-	NA
PBT before Joint Venture	1,818	920	97.6%
Share of JV	143	(24)	NA
PBT	1,961	896	118.9%
Tax Expense	485	230	110.9%
PAT	1,476	666	121.6%
PAT Margin (%)	12.88%	8.28%	460 Bps
Other Comprehensive Income	(9)	1	NA
Total Comprehensive Income	1,467	667	119.9%
Diluted EPS (INR)	16.26	7.33	121.8%

Recognition of fair value movement on a long-dated USD forward contract under FVTPL impacted reported profitability during the period, with previous quarterly figures restated accordingly.

HISTORICAL CONSOLIDATED INCOME STATEMENT

PARTICULARS (INR Mn)	H1-FY27	FY26	FY25*	FY24*
Operational Revenue	11,462	18,194	21,151	18,526
Operating Expenses	8,789	14,170	16,507	14,666
EBITDA	2,673	4,024	4,644	3,860
EBITDA Margin (%)	23.32%	22.12%	21.96%	20.84%
Depreciation and Amortisation	606	1,043	869	732
Finance costs	278	469	269	172
Foreign Exchange (Gain)/Loss	(40)	332	(17)	-
Other Income	9	97	84	49
PBT before Joint Venture & Exceptional Items	1,838	2,277	3,607	3,005
Exceptional Items (Net of Tax Expenses)	(20)	28	-	-
PBT before Joint Venture	1,818	2,249	3,607	3,005
Share of JV	143	80	-	-
PBT	1,961	2,329	3,607	3,005
Tax Expense	485	582	883	836
PAT	1,476	1,747	2,724	2,169
PAT Margin (%)	12.88%	9.60%	12.88%	11.71%
Other Comprehensive Income	(9)	(62)	(98)	(4)
Total Comprehensive Income	1,467	1,685	2,626	2,165
Diluted EPS (INR)	16.26	19.25	30.04	23.93

*Note: As intimated to the stock exchange on 1st April 2025, regarding the addendum to the SHA with Ganesh Polychem Limited, the entity becomes a joint venture of the company with effect from April 1, 2025, and pursuant to the same the consolidated accounts are prepared using the equity method of accounting as required by the relevant Ind AS. Accordingly, current period numbers are not comparable with previous periods.

HISTORICAL CONSOLIDATED BALANCE SHEET

ASSETS (INR Mn)	FY25*	FY26	H1-FY27
Non-current assets			
Property, plant and equipment	10,887	13,359	14,092
Capital work-in-progress	3,066	3,052	3,082
Right-to-use assets	154	655	567
Goodwill	18	-	-
Other Intangible assets	307	360	346
Intangible assets under development	678	879	1,039
Financial assets			
Investments (others)	292	1,938	2,038
Loans	73	78	80
Other Financial Assets	140	354	363
Other non-current assets	227	169	86
Total of Non-current assets	15,842	20,844	21,693
Current assets			
Inventories	5,876	6,403	7,942
Financial assets			
Investments	476	-	-
Trade receivables	5,754	5,833	6,850
Cash and cash equivalents	67	85	42
Bank balances other than above	19	11	191
Loans	10	5	6
Other financial assets	12	-	2
Other current assets	968	1,537	1,533
Current Tax Assets (Net)	-	99	-
Total Current assets	13,182	13,973	16,566
Total Assets	29,024	34,817	38,259


EQUITY & LIABILITIES (INR Mn)	FY25*	FY26	H1-FY27
Equity share capital	453	453	453
Other equity	19,446	20,793	22,094
Total Equity	19,899	21,246	22,547
Liabilities			
Non-current liabilities			
Financial liabilities			
Borrowings	1,036	1,858	1,598
Lease liabilities	117	522	435
Non Current financial liabilities	77	394	368
Provisions	81	78	91
Deferred Tax Liabilities (Net)	1,284	1,343	1,426
Total of Non-current liabilities	2,595	4,195	3,918
Current liabilities			
Financial liabilities			
Borrowings	2,928	4,998	6,766
Lease liabilities	51	166	172
Trade Payables	2,778	3,346	3,634
Other financial liabilities	474	651	783
Provisions	117	112	190
Current Tax Liabilities (Net)	11	-	215
Other Current Liabilities	171	103	34
Total of Current liabilities	6,530	9,376	11,794
Total Liabilities	9,125	13,571	15,712
Total Equity & Liabilities	29,024	34,817	38,259

*Note: As intimated to the stock exchange on 1st April 2025, regarding the addendum to the SHA with Ganesh Polychem Limited, the entity becomes a joint venture of the company with effect from April 1, 2025, and pursuant to the same the consolidated accounts are prepared using the equity method of accounting as required by the relevant Ind AS. Accordingly, current period numbers are not comparable with previous periods.


CONSOLIDATED FINANCIAL HIGHLIGHTS




OPERATIONAL INCOME (INR Mn)




EBITDA (INR Mn) & EBITDA MARGINS (%)




PAT (INR Mn) & PAT MARGINS (%)



Net Debt to Equity (X)



ROCE (%) & ROE (%)




**Note: As intimated to the stock exchange on 1st April 2025, regarding the addendum to the SHA with Ganesh Polychem Limited, the entity becomes a joint venture of the company with effect from April 1, 2025, and pursuant to the same the consolidated accounts are prepared using the equity method of accounting as required by the relevant Ind AS. Accordingly, current period numbers are not comparable with previous periods.*

CAPITAL MARKET INFORMATION




SHARE PRICE UP TO 30th September, 2026



PRICE DATA (AS ON 30 th September, 2026)	INR
Face Value	5.00
Market Price	952.25
52 Week H/L	1,001.55 / 583.85
Market Cap (Mn)	86,349.85
Equity Shares Outstanding (Mn)	90.66
1 Year Avg Trading Volume ('000)	380.48

SHAREHOLDING PATTERN (AS ON 30th September, 2026)



DISCLAIMER



Aarti Pharmalabs Limited

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements" based on the currently held beliefs and assumptions of the management of Aarti Pharmalabs Ltd. (Company), which are expressed in good faith and in their opinion reasonable, including those relating to the Company's general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment.

Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company or industry results to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company's business, its competitive environment and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments.

This presentation is confidential and may not be copied or disseminated, in whole or in part, and in any manner.

Valorem Advisors Disclaimer:

Valorem Advisors is an Independent Investor Relations Management Service company. This Presentation has been prepared by Valorem Advisors based on information and data which the Company considers reliable, but Valorem Advisors and the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Valorem Advisors also hereby certifies that the directors or employees of Valorem Advisors do not own any stock in personal or company capacity of the Company under review.

For further details, please feel free to contact our Investor Relations Representatives:



Mr. Anuj Sonpal
Valorem Advisors

Tel: +91-22-3507 5100

Email : aarti@valoremadvisors.com

To access the Investor Kit link and/or request a meeting click here: <https://www.valoremadvisors.com/aarti>



THANK YOU

AARTI PHARMALABS LIMITED